BioSpecifics Technologies Corp. Company Profile (NASDAQ:BSTC)

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. logoBioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren's contracture and Peyronie's disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren's contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BSTC
  • CUSIP: 09093110
Key Metrics:
  • Previous Close: $50.46
  • 50 Day Moving Average: $52.12
  • 200 Day Moving Average: $46.97
  • 52-Week Range: $7,147,000.00 - $31.32
  • Trailing P/E Ratio: 33.20
  • Foreward P/E Ratio: 29.17
  • P/E Growth: 1.48
  • Market Cap: $360.64M
  • Outstanding Shares: 7,147,000
  • Beta: 1.31
Profitability:
  • Net Margins: 43.13%
  • Return on Equity: 22.74%
  • Return on Assets: 19.88%
Debt:
  • Current Ratio: 21.57%
  • Quick Ratio: 21.57%
Additional Links:
Companies Related to BioSpecifics Technologies Corp.:

Analyst Ratings

Consensus Ratings for BioSpecifics Technologies Corp. (NASDAQ:BSTC) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.00 (18.91% upside)

Analysts' Ratings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Show:
DateFirmActionRatingPrice TargetDetails
10/6/2016HC WainwrightReiterated RatingBuy$60.00View Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00View Rating Details
7/16/2015MLV & Co.Initiated CoverageBuy$76.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.21$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.09$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.12$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25ViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Current Year EPS Consensus Estimate: $1.55 EPS
Next Year EPS Consensus Estimate: $1.73 EPS

Dividends

Dividend History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Insider Ownership Percentage: 23.19%
Institutional Ownership Percentage: 54.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
DateHeadline
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events (NASDAQ:BSTC)
biz.yahoo.com - February 16 at 8:54 AM
News IconDoes BioSpecifics Technologies Corp. (BSTC) Have Any Gas After Forming This Wedge Up? (NASDAQ:BSTC)
randolphguide.com - January 31 at 4:26 PM
capitalcube.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : January 31, 2017 (NASDAQ:BSTC)
www.capitalcube.com - January 31 at 4:26 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference (NASDAQ:BSTC)
finance.yahoo.com - January 24 at 4:35 PM
capitalcube.com logoBiospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : January 19, 2017 (NASDAQ:BSTC)
www.capitalcube.com - January 19 at 5:10 PM
capitalcube.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : January 18, 2017 (NASDAQ:BSTC)
www.capitalcube.com - January 18 at 3:29 PM
marketexclusive.com logoBIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD Disclosure (NASDAQ:BSTC)
marketexclusive.com - January 9 at 5:09 PM
News IconIs BioSpecifics Technologies Corp. (BSTC) A Good Stock To Buy Right Now? (NASDAQ:BSTC)
feedproxy.google.com - December 15 at 8:47 AM
capitalcube.com logoETFs with exposure to Biospecifics Technologies Corp. : December 2, 2016 (NASDAQ:BSTC)
www.capitalcube.com - December 2 at 4:27 PM
capitalcube.com logoBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 (NASDAQ:BSTC)
www.capitalcube.com - November 22 at 3:30 PM
streetinsider.com logoBiospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with Cellulite (NASDAQ:BSTC)
www.streetinsider.com - November 19 at 12:23 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite (NASDAQ:BSTC)
finance.yahoo.com - November 18 at 12:31 PM
finance.yahoo.com logoWill BioSpecifics Technologies (BSTC) Continue to Surge Higher? (NASDAQ:BSTC)
finance.yahoo.com - November 18 at 12:31 PM
News IconBioSpecifics Technologies Corp. BSTC Financial and Strategic SWOT Analysis Review Prices from USD $125 (NASDAQ:BSTC)
www.bioportfolio.com - November 17 at 1:31 PM
finance.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Financials (NASDAQ:BSTC)
finance.yahoo.com - November 17 at 1:31 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BSTC)
biz.yahoo.com - November 14 at 7:32 AM
seekingalpha.com logoBioSpecifics Technologies' (BSTC) Management on Q3 2016 Results - Earnings Call Transcript (NASDAQ:BSTC)
seekingalpha.com - November 10 at 3:21 PM
News IconBioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results (NASDAQ:BSTC)
www.kait8.com - November 9 at 8:49 PM
sg.finance.yahoo.com logoBioSpecifics posts 3Q profit (NASDAQ:BSTC)
sg.finance.yahoo.com - November 9 at 8:49 PM
biz.yahoo.com logoQ3 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open (NASDAQ:BSTC)
biz.yahoo.com - November 9 at 1:04 PM
capitalcube.com logoETF’s with exposure to Biospecifics Technologies Corp. : November 9, 2016 (NASDAQ:BSTC)
www.capitalcube.com - November 9 at 1:04 PM
capitalcube.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : November 8, 2016 (NASDAQ:BSTC)
www.capitalcube.com - November 8 at 2:46 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at Stifel 2016 Healthcare Conference (NASDAQ:BSTC)
finance.yahoo.com - November 8 at 2:46 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:BSTC)
biz.yahoo.com - November 7 at 3:35 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results on Wednesday, November … (NASDAQ:BSTC)
finance.yahoo.com - November 2 at 3:39 PM
publicnow.com logoBioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016 (NASDAQ:BSTC)
www.publicnow.com - November 2 at 11:44 AM
capitalcube.com logoTop 5 valuable Pharma stocks : October 24, 2016 (NASDAQ:BSTC)
www.capitalcube.com - October 24 at 3:56 PM
capitalcube.com logoETF’s with exposure to Biospecifics Technologies Corp. : October 20, 2016 (NASDAQ:BSTC)
www.capitalcube.com - October 20 at 3:29 PM
finance.yahoo.com logoBioSpecifics Technologies (BSTC) Catches Eye: Stock Up 5.2% (NASDAQ:BSTC)
finance.yahoo.com - September 21 at 3:25 PM
finance.yahoo.com logoCan The Uptrend Continue for BioSpecifics Technologies (BSTC)? (NASDAQ:BSTC)
finance.yahoo.com - September 20 at 9:52 AM
zacks.com logoFoamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7% (NASDAQ:BSTC)
www.zacks.com - September 13 at 8:51 AM
zacks.com logoNew Strong Buy Stocks for September 7th (NASDAQ:BSTC)
www.zacks.com - September 7 at 10:32 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences (NASDAQ:BSTC)
finance.yahoo.com - September 2 at 8:44 AM
zacks.com logoDipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5% (NASDAQ:BSTC)
www.zacks.com - September 1 at 12:28 PM
finance.yahoo.com logoWhat Makes Collegium Pharmaceutical (COLL) a Strong Sell? (NASDAQ:BSTC)
finance.yahoo.com - August 30 at 11:48 AM
zacks.com logoWeakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away? (NASDAQ:BSTC)
www.zacks.com - August 29 at 3:20 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences (NASDAQ:BSTC)
finance.yahoo.com - August 29 at 3:20 PM
capitalcube.com logoETF’s with exposure to Biospecifics Technologies Corp. : August 23, 2016 (NASDAQ:BSTC)
www.capitalcube.com - August 23 at 4:02 PM
capitalcube.com logoBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:BSTC)
www.capitalcube.com - August 12 at 3:27 PM
sg.finance.yahoo.com logoBioSpecifics posts 2Q profit (NASDAQ:BSTC)
sg.finance.yahoo.com - August 9 at 10:35 PM
publicnow.com logoBioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results (NASDAQ:BSTC)
www.publicnow.com - August 9 at 5:06 PM
biz.yahoo.com logoQ2 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open (NASDAQ:BSTC)
biz.yahoo.com - August 9 at 12:56 PM
seekingalpha.com logoBioSpecifics Technologies Corp. Has A 6-Year Expiration Date (NASDAQ:BSTC)
seekingalpha.com - August 3 at 12:41 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, … (NASDAQ:BSTC)
finance.yahoo.com - August 2 at 4:06 PM
publicnow.com logoBioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016 (NASDAQ:BSTC)
www.publicnow.com - August 2 at 8:47 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma (NASDAQ:BSTC)
finance.yahoo.com - June 13 at 4:14 PM
feeds.benzinga.com logoBioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma (NASDAQ:BSTC)
feeds.benzinga.com - June 13 at 10:19 AM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:BSTC)
biz.yahoo.com - June 3 at 1:09 PM
streetinsider.com logoBiospecifics Technologies (BSTC) Announces Publication of Data for Uterine Fibroid Treatment with CCH (NASDAQ:BSTC)
www.streetinsider.com - May 31 at 4:00 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BSTC)
biz.yahoo.com - May 31 at 3:04 PM

Social

What is BioSpecifics Technologies Corp.'s stock symbol?

BioSpecifics Technologies Corp. trades on the NASDAQ under the ticker symbol "BSTC."

Where is BioSpecifics Technologies Corp.'s stock going? Where will BioSpecifics Technologies Corp.'s stock price be in 2017?

2 equities research analysts have issued 12-month price targets for BioSpecifics Technologies Corp.'s stock. Their predictions range from $60.00 to $60.00. On average, they anticipate BioSpecifics Technologies Corp.'s share price to reach $60.00 in the next twelve months.

When will BioSpecifics Technologies Corp. announce their earnings?

BioSpecifics Technologies Corp. is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.66%), Dimensional Fund Advisors LP (3.21%), Numeric Investors LLC (2.16%), State Street Corp (1.15%), JW Asset Management LLC (1.03%) and RK Capital Management LLC (0.99%). Company insiders that own BioSpecifics Technologies Corp. stock include Paul Gitman, Thomas Wegman and Toby Wegman.

Who sold BioSpecifics Technologies Corp. stock? Who is selling BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock was sold by a variety of institutional investors in the last quarter, including RK Capital Management LLC, Royce & Associates LP, Two Sigma Investments LP, Oxford Asset Management, Allianz Asset Management AG, GSA Capital Partners LLP, Hatteras Funds LP and Putnam Investments LLC. Company insiders that have sold BioSpecifics Technologies Corp. stock in the last year include Thomas Wegman and Toby Wegman.

Who bought BioSpecifics Technologies Corp. stock? Who is buying BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Cigna Investments Inc. New, AQR Capital Management LLC, State Street Corp and A.R.T. Advisors LLC.

How do I buy BioSpecifics Technologies Corp. stock?

Shares of BioSpecifics Technologies Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioSpecifics Technologies Corp. stock cost?

One share of BioSpecifics Technologies Corp. stock can currently be purchased for approximately $50.46.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Earnings History Chart

Earnings by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Dividend History Chart

Dividend Payments by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Last Updated on 2/26/2017 by MarketBeat.com Staff